3 hours ago · Global
‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows
What's happening
SignalsMonitor is following this as a general story. The Guardian UK is the outlet attached so far. The reports are tied to Global. The first report grouped here was at 23 Oct 2026, 04:27 UTC. The headline in use is “‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
Trial results represent ‘foundational shift’ in approach to cancer, allowing scientists to harness immune system in more personalised way Get our new political email, free app or daily news podcast A personalised mRNA-based melanoma vaccine significantly reduces the risk of cancer recurrence or death within two years, new clinical trial…
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by The Guardian UK
Reported by 1 outlet
- The Guardian